Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2014
Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study.
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Database of Data Collection in Senological Surgery
Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemotherapy and a Diet Mimicking FASTing Plus/Minus Metformin in the Preoperative Setting: the BREAKFAST Trial
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- Small Triple-Negative and HER2-Positive Early Breast Cancer: Upfront Surgery or Neoadjuvant Chemotherapy?Cancers · 2026Review
- De-escalating axillary surgery in early breast cancer: external validation of a retrospective cohort.Journal of cancer research and clinical oncology · 2026Observational
- Prognostic impact of extensive nodal involvement in small-sized (T1) breast cancer: a population-based and propensity score-matched analysis of the SEER database.Gland surgery · 2026Article
- MRI radiomics for diagnosing small BI-RADS 4 breast lesions: an interpretable model.Quantitative imaging in medicine and surgery · 2025Article
- Benefit of adjuvant chemotherapy for T1cN0M0 and selected T1bN0M0 triple-negative breast cancer: a nationwide cancer registry-based study.The oncologist · 2025Article
- Comparative Analysis of Automated and Handheld Breast Ultrasound Findings for Small (≤1 cm) Breast Cancers Based on BI-RADS Category.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer.Breast cancer research and treatment · 2024Article
- Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer.Breast cancer research and treatment · 2023Article
- Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment.Frontiers in oncology · 2023Article
- Impact of contrast-enhanced mammography in surgical management of breast cancers for women with dense breasts: a dual-center, multi-disciplinary study in Asia.European radiology · 2022Article
- Is 9-G DBT-Guided Vacuum-Assisted Breast Biopsy Sufficient to Completely Remove T1 Breast Cancers (below 20 mm)? Analysis of 146 Patients with Histology as Reference Standard.Breast care (Basel, Switzerland) · 2022Article
- Chemotherapy significantly improves long-term survival of small lesion node negative metaplastic breast carcinoma in T1c population rather than T1a and T1b.Scientific reports · 2022Article
- Preoperative prediction of lymphovascular invasion in patients with T1 breast invasive ductal carcinoma based on radiomics nomogram using grayscale ultrasound.Frontiers in oncology · 2022Article
- Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment.Frontiers in oncology · 2021Article
- Characteristics and clinical outcome of pT1a-b node-negative breast cancer.Northern clinics of Istanbul · 2021Article
- Novel prognostic nomograms for female patients with breast cancer and bone metastasis at presentation.Annals of translational medicine · 2020Article
- Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis.Journal of oncology · 2020Article
- The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy.Frontiers in oncology · 2020Article
- Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA subgroup of T1N0M0 breast cancer (BC) carries a high potential of relapse, and thus may require adjuvant systemic therapy (AST). PATIENTS AND
methodsRetrospective analysis of all patients with T1 BC, who underwent surgery from January 1999 to December 2009 at 13 French sites. AST was not standardized.
resultsAmong 8100 women operated, 5423 had T1 tumors (708 T1a, 2208 T1b and 2508 T1c 11-15 mm). T1a differed significantly from T1b tumors with respect to several parameters (lower age, more frequent negative hormonal status and positive HER2 status, less frequent lymphovascular invasion), exhibiting a mix of favorable and poor prognosis factors. Overall survival was not different between T1a, b or c tumors but recurrence-free survival was significantly higher in T1b than in T1a tumors (P = 0.001). In multivariate analysis, tumor grade, hormone therapy and lymphovascular invasion were independent prognostic factors.
conclusionRelatively poor outcome of patients with T1a tumors might be explained by a high frequency of risk factors in this subgroup (frequent negative hormone receptors and HER2 overexpression) and by a less frequent administration of AST (endocrine treatment and chemotherapy). Tumor size might not be the main determinant of prognosis in T1 BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.